



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | |
|--|------------------------|---------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i> | Application Number | 10597373 |
| | Filing Date | 2006-07-21 |
| | First Named Inventor | MEDOF, Edward |
| | Art Unit | 1646 |
| | Examiner Name | |
| | Attorney Docket Number | 200512.00047 |

| U.S.PATENTS | | | | | | |
|-------------------|---------|---------------|------------------------|------------|---|--|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
| | 1 | | | | | |

If you wish to add additional U.S. Patent citation information please click the Add button.

| U.S.PATENT APPLICATION PUBLICATIONS | | | | | | |
|-------------------------------------|---------|--------------------|------------------------|------------------|---|--|
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
| | 1 | | | | | |

If you wish to add additional U.S. Published Application citation information please click the Add button.

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|---------|--------------------------------------|---------------------------|------------------------|------------------|---|--|
| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
| | 1 | | | | | | T5 |

If you wish to add additional Foreign Patent Document citation information please click the Add button

| NON-PATENT LITERATURE DOCUMENTS | | | | | | | |
|---------------------------------|---------|---|--|--|--|--|----|
| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | | | | | T5 |
| | | | | | | | |



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|---------------|
| Application Number | 10597373 |
| Filing Date | 2006-07-21 |
| First Named Inventor | MEDOF, Edward |
| Art Unit | 1646 1644 |
| Examiner Name | Huynh, Phuong |
| Attorney Docket Number | 200512.00047 |

| | | |
|----|---|--------------------------|
| 1 | KUTTNER-KONDO and MEDOF; "Engineering of DAF-CR1 and DAF-MCP hybrid proteins for enhanced function;" Abstracts/Molecular Immunology; 2004; pgs. 264-265 (Abstract #138); Vol. 41 | <input type="checkbox"/> |
| 2 | WEISMAN et al.; "Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis;" Science; July 13, 1990; pgs. 146-151; Vol. 249 | <input type="checkbox"/> |
| 3 | KALLI et al.; "Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor;" J. Exp. Med.; December 1991; pgs. 1451-1460; Vol. 174; The Rockefeller University Press | <input type="checkbox"/> |
| 4 | SONG et al.; "Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation;" The Journal of Clinical Investigation; June 2003; pgs. 1875-1885; Vol. 111, No. 12 | <input type="checkbox"/> |
| 5 | FODOR et al.; "A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex;" The Journal of Immunology; 1995; pgs. 4135-4138; Vol. 155; The American Association of Immunologists | <input type="checkbox"/> |
| 6 | HIGGINS et al.; "A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities;" The Journal of Immunology; 1997; pgs. 2872-2881; Vol. 158; The American Association of Immunologists; U.S.A. | <input type="checkbox"/> |
| 7 | SALERNO et al.; "A soluble chimeric inhibitor of C3 and C5 convertases, complement activation blocker-2, prolongs graft survival in pig-to-rhesus monkey heart transplantation;" Xenotransplantation; 2002; pgs. 125-134; Vol. 9; United Kingdom | <input type="checkbox"/> |
| 8 | KROSHUS et al.; "A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation;" Transplantation; June 15, 2000; pgs. 2282-2289; Vol. 69, No. 11; Lippincott Williams & Wilkins, Inc.; U.S.A. | <input type="checkbox"/> |
| 9 | LI et al.; "Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass;" American Heart Journal; January 2004; pgs. 173-180; Vol. 147; Elsevier Inc., U.S.A. | <input type="checkbox"/> |
| 10 | LAZAR et al.; "Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass;" Circulation; September 14, 2004; pgs. II274-II279; Issue No. 0009-7322; Vol. 110 (Suppl II); The American Heart Association; Dallas, TX U.S.A. | <input type="checkbox"/> |
| 11 | SCHMID et al.; "TP20 is superior to TP10 in reducing ischemia/reperfusion injury in rat lung grafts;" Transplantation Proceedings; 2001; pgs. 948-949; Vol. 33; Elsevier Science Inc.; New York, NY U.S.A. | <input type="checkbox"/> |

NOV 07 2006

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|---------------|
| Application Number | 10597373 |
| Filing Date | 2006-07-21 |
| First Named Inventor | MEDOF, Edward |
| Art Unit | 1646 |
| Examiner Name | |
| Attorney Docket Number | 200512.00047 |

| | | |
|----|---|--------------------------|
| 12 | ZIMMERMAN et al.; "Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome;" Crit Care Med; 2000; pgs. 3149-3154; Vol. 28, No. 9; Lippincott Williams & Wilkins; U.S.A. | <input type="checkbox"/> |
| 13 | COUSER et al.; "The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis;" Journal of the American Society of Nephrology; 1995; pgs. 1888-1894; Vol. 5, No. 11; The American Society of Nephrology; U.S.A. | <input type="checkbox"/> |
| 14 | KRYCH-GOLDBERG et al.; "Synergy between two active sites of human complement receptor type 1 (CD35) in complement regulation: implications for the structure of the classical pathway C3 convertase and generation of more potent inhibitors;" Journal of Immunology; 2005; pgs. 4528-4535; Vol. 175; The American Association of Immunologists, Inc. U.S.A. | <input type="checkbox"/> |
| 15 | HARRIS et al.; "Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo;" Clinical and Experimental Immunology; 2002; pgs. 198-207; Vol. 129; Blackwell Science | <input type="checkbox"/> |
| 16 | HARRIS et al.; "Generation of anti-complement "prodrugs": cleavable reagents for specific delivery of complement regulators to disease sites;" Journal of Biological Chemistry; September 19, 2003; pgs. 36068-36076; Vol. 278, No. 38; The American Society for Biochemistry and Molecular Biology, Inc.; U.S.A. | <input type="checkbox"/> |
| 17 | IWATA et al.; "Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese Hamster Ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein;" Journal of Immunology; 1994; pgs. 3436-3444; Vol. 152; The American Association of Immunologists; U.S.A. | <input type="checkbox"/> |
| 18 | CHRISTIANSEN et al.; "Engineering of recombinant soluble CD46: an inhibitor of complement activation;" Immunology; 1996; pgs. 348-354; Vol. 87; Blackwell Science Ltd. | <input type="checkbox"/> |
| 19 | RINDER et al.; "Role of C3 cleavage in monocyte activation during extracorporeal circulation;" Circulation; August 3, 1999; pgs. 553-558; Vol. 100; American Heart Association, Inc.; Dallas, TX U.S.A. | <input type="checkbox"/> |
| 20 | SOUZA et al; "APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury;" British Journal of Pharmacology; 2005; pgs. 1027-1034; Vol. 145; Nature Publishing Group | <input type="checkbox"/> |
| 21 | LAM et al.; "The effect of soluble complement receptor type 1 on acute humoral xenograft rejection in hDAF-transgenic pig-to-primate life-supporting kidney xenografts;" Xenotransplantation; 2005; pgs. 20-29; Vol. 12; Singapore | <input type="checkbox"/> |
| 22 | HENRY et al.; "Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide;" International Immunopharmacology; 2002, pgs. 1657-1666; Elsevier Science B.V. | <input type="checkbox"/> |

NOV 07 2006

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|---------------|
| Application Number | 10597373 |
| Filing Date | 2006-07-21 |
| First Named Inventor | MEDOF, Edward |
| Art Unit | 1646 |
| Examiner Name | |
| Attorney Docket Number | 200512.00047 |

| | | |
|----|--|--------------------------|
| 23 | VON DOBSCHUETZ et al.; "Soluble complement receptor 1 preserves endothelial barrier function and microcirculation in postischemic pancreatitis in the rat;" American Journal of Physiology - Gastrointestinal Liver Physiology; December 23, 2003; pgs. 791-796; Vol. 286; American Physiological Society; Bethesda, MD U.S.A. | <input type="checkbox"/> |
| 24 | YAZDANBAKHS, KARINA; "Development of complement therapeutics for inhibition of immune-mediated red cell destruction;" Transfusion; August 2005; pgs. 122S-129S; Vol. 45 | <input type="checkbox"/> |
| 25 | XOMA Ltd.; "MLN01 and CAB-2 with Millennium Pharmaceuticals, Inc.;" Press Release; May 15, 2003; pg. 2; U.S.A. | <input type="checkbox"/> |
| 26 | BIOSPACE BEAT; "XOMA (XOMA) and Millennium Pharmaceuticals, Inc. (California) (MLNM) announce initiation of phase I clinical trial of MLN2222 – A.K.A. CAB-2 – a novel complement inhibitor;" Press Release; December 18, 2003; U.S.A. | <input type="checkbox"/> |
| 27 | AVANT IMMUNOTHERAPEUTICS, INC.; www.avantimmune.com/products/tp10.html and www.avantimmune.com/products/tp20.html | <input type="checkbox"/> |

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

| | | | |
|--------------------|----------------|-----------------|------------|
| Examiner Signature | /Phuong Huynh/ | Date Considered | 04/27/2010 |
|--------------------|----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.